1
2
3
4
5
6
7
8
9
10
11

Mirum Pharmaceuticals is dedicated to creating life-changing therapies for patients with liver diseases.

12
13
14
15
Extra 1

Our medicines are designed to address the severe itching and progressive liver damage of cholestatic liver diseases for children like Trey.

16
17
18

We don’t just work on behalf of patients, we work with them. We are currently recruiting patients for clinical trials.

placeholder

An Open Letter to Our Patients, Their Families, Healthcare Providers and Other Stakeholders from Mirum CEO Chris Peetz

At Mirum Pharmaceuticals, the health and welfare of our patients and employees is a top priority. We are taking appropriate precautions to protect the safety and health of those around us, while ensuring that patients participating in our studies have continued access to Mirum’s investigational treatments.

An Open Letter to Our Patients, Their Families, Healthcare Providers and Other Stakeholders from Mirum CEO Chris Peetz

At Mirum Pharmaceuticals, the health and welfare of our patients and employees is a top priority. We are taking appropriate precautions to protect the safety and health of those around us, while ensuring that patients participating in our studies have continued access to Mirum’s investigational treatments.

While the coronavirus pandemic has led to suspended activities and business around the world, our goal is to maintain uninterrupted supply of investigational treatments to those patients who are enrolled in our clinical studies. To address these ongoing needs, we are working closely with healthcare providers, our third-party manufacturers, and our study service providers to minimize disruption while supporting our communities’ efforts to slow the spread of the virus. Caregivers of children currently participating in a Mirum clinical study should continue to follow the advice of their healthcare provider and are encouraged to speak with them if they have any concerns.

We continue to focus on our planned rolling submission of a New Drug Application to the U.S. Food and Drug Administration for Alagille syndrome beginning in the third quarter of 2020. For caregivers and healthcare providers interested in our planned Alagille syndrome expanded access program, we encourage you to visit www.algseap.com for updates on the program’s availability. Additionally, our plans to present and publish data throughout the year currently remains intact.

Given the uncertainty surrounding this evolving pandemic, we are actively assessing the impact the virus will have on our work here at Mirum, including to our Phase 3 PFIC study, MARCH. For caregivers and physicians looking for more information on the MARCH study, please email us at clinicaltrials@mirumpharma.com or visit www.pfictrial.com.

In the meantime, we are conducting an analysis of our long-term maralixibat treatment data in PFIC against a natural history control group in conjunction with the NAtural course and Prognosis of PFIC and Effect of biliary Diversion (NAPPED) Consortium and plan to share these results with regulators in 2020.

As we navigate the coronavirus pandemic, our commitment remains to bring new medicines to patients to address devastating diseases. We will continue to work tirelessly to ensure we are doing everything we can for our patients, caregivers, healthcare providers, employees and community.

Stay safe.
Chris

Latest News

  • Mirum Pharmaceuticals to Present at Upcoming Investor Conferences

    November 23, 2020

  • Mirum Pharmaceuticals Announces Data Presented During AASLD Highlighting Durable Improvements in Pruritus and Quality of Life in Children with Alagille Syndrome Treated with Maralixibat

    November 15, 2020

  • Mirum Pharmaceuticals Presents New Data From Its Maralixibat and Volixibat Clinical Studies at AASLD Annual Meeting

    November 13, 2020

  • Mirum Pharmaceuticals Provides Third Quarter 2020 Financial Results and Business Update, and Announces Virtual Investor Day

    November 12, 2020

  • Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    November 10, 2020

© 2020 – Mirum Pharmaceuticals